Hepatitis CTreatment

How Hep C Treatment Has Gotten So Much Better Over the Years

one yellow tree surrounded by green trees
Christopher Rusev

woman sick under blanket on couch

Early Days of HCV Treatment Were Rough

woman taking pill that looks like Victrelis

The Breakthrough: Direct-Acting Antivirals

tired man on bench

New Hep C Drugs Have Fewer Side Effects

silhouette of two men high-fiving
Tyler Nix

Today's DAAs Are More Effective

yellow flowers with one tall purple flower sticking out
Dan Meyers

DAAs Don’t Act the Same Way as Older Meds

smiling woman
Rafael Barros

Older Meds Had Mental Health Side Effects

man in the dark looking to light
Ahmed Hasan

Now: DAAs Offer Real Hope to Patients

red sand hourglass

Now: DAAs Have a Shorter Treatment Time

Pill Box And Medication Sitting On Top Of A Bedside Nightstand

You’re More Likely to See Treatment Through

Syringe and Pills

Current Hep C Meds Are Easier to Take

woman with headache

Bottom Line: No Drug Is Perfect

  • HCV Becomes a Diagnosis: Mini-Reviews in Medicinal Chemistry. (2018). “Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy,”

  • Interferon’s Early Days: Hepatitis Research and Treatment. (2010). “Treatment of Hepatitis C Infections with Interferon: A Historical Perspective,”

  • Newer DAAs Enter the Scene: Gastroenterology & Hepatology. “New Therapies for Hepatitis C Virus Infection,”

  • First-Generation Protease Inhibitors Discontinued: GoodRx. (2015). Victrelis: Another Hepatitis C Medication Discontinued.

  • New Hep C treatments have Few to No Serious Side Effects: The New England Journal of Medicine. (2014) “Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis,”

  • DAAs Don’t Act the Same Way as Older Meds: UpToDate. (2019). “Direct-acting antivirals for the treatment of hepatitis C virus infection,”

  • DAAs have Fewer Mental Health Side Effects. Annals of Gastroenterology. (2015). “Depression and suicide ideation in chronic hepatitis C patients untreated and treated with interferon: prevalence, prevention, and treatment,”

Erin L. Boyle

Erin L. Boyle


Erin L. Boyle, the senior editor at HealthCentral from 2016-2018, is an award-winning freelance medical writer and editor with more than 15 years’ experience. She’s traveled the world for a decade to bring the latest in medical research to doctors. Health writing is also personal for her: she has several autoimmune diseases and migraines with aura, which she writes about for HealthCentral. Learn more about her at Follow her on Twitter @ErinLBoyle.